RT Journal Article
T1 Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis.
A1 Cañete, Fiorella
A1 Mañosa, Míriam
A1 Perez-Martinez, Isabel
A1 Barreiro-de-Acosta, Manuel
A1 Gonzalez-Sueyro, Ramiro C
A1 Nos, Pilar
A1 Iglesias-Flores, Eva
A1 Gutierrez, Ana
A1 Bujanda, Luis
A1 Gordillo, Jordi
A1 Rios-Leon, Raquel
A1 Casanova, Maria Jose
A1 Villoria, Albert
A1 Rodriguez-Lago, Iago
A1 Lopez-Serrano, Pilar
A1 Garcia-Herola, Antonio
A1 Ramirez-de-la-Piscina, Patricia
A1 Navarro-Llavat, Merce
A1 Taxonera, Carlos
A1 Barrio, Jesus
A1 Ramos, Laura
A1 Navarro, Pablo
A1 Benitez-Leiva, Olga
A1 Calafat, Margalida
A1 Domenech, Eugeni
K1 Anti-Inflammatory Agents
K1 Colonoscopy
K1 Crohn Disease
K1 Immunosuppressive Agents
K1 Intestinal Mucosa
K1 Recurrence
K1 Retrospective Studies
AB Patients with Crohn's disease experiencing endoscopic postoperative recurrence (POR) may benefit from antitumor necrosis factor (TNF) agents but scarce data on this are available. Our aim was to assess the efficacy of anti-TNF in improving mucosal lesions in patients with endoscopic POR. Multicenter, retrospective, study of patients with Crohn's disease who underwent therapy with anti-TNF agents for endoscopic POR (Rutgeerts score > i1). Treatment outcomes were assessed by the findings in the last ileocolonoscopy performed after anti-TNF therapy was initiated. Endoscopic improvement and remission were defined as any reduction in the baseline Rutgeerts score and by a Rutgeerts score  i1). Treatment outcomes were assessed by the findings in the last ileocolonoscopy performed after anti-TNF therapy was initiated. Endoscopic improvement and remission were defined as any reduction in the baseline Rutgeerts score and by a Rutgeerts score  A total of 179 patients were included, 83 were treated with infliximab and 96 with adalimumab. Median time on anti-TNF therapy at the last endoscopic assessment was 31 months (interquartile range, 13-54). Endoscopic improvement was observed in 61%, including 42% who achieved endoscopic remission. Concomitant use of thiopurines and treatment with infliximab were associated with endoscopic improvement (odds ratio [OR] 2.15, 95% confidence interval [CI] 1.04-4.46; P = 0.03, and OR 2.34, 95% CI 1.18-4.62; P  In patients with endoscopic POR, anti-TNF agents improve mucosal lesions in almost two-thirds of the patients. In this setting, concomitant use of thiopurines and use of infliximab seem to be more effective in improving mucosal lesions.
PB Wolters Kluwer Health
YR 2020
FD 2020-08-03
LK https://hdl.handle.net/10668/27949
UL https://hdl.handle.net/10668/27949
LA en
NO Cañete F, Mañosa M, Pérez-Martínez I, Barreiro-de Acosta M, González-Sueyro RC, Nos P, et al. Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis. Clin Transl Gastroenterol. 2020 Aug;11(8):e00218.
DS RISalud
RD Apr 6, 2025